TITLE

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

AUTHOR(S)
Scirica, Benjamin M.
PUB. DATE
September 2012
SOURCE
Cardiologia Croatica;2012, Vol. 7 Issue 9/10, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the clinical trial for vorapaxar for secondary prevention in patients with prior myocardial infarction.
ACCESSION #
84508532

 

Related Articles

  • Study Supports More Appropriate Blood Pressure Levels for Post-ACS Patients. Crawford, Michael H. // Hospital Medicine Alert;Feb2011, Vol. 5 Issue 12, p91 

    The article discusses a study that supports a data about blood pressure levels for post-acute coronary syndromes (ACS) patients. The author remarks that the study further supports the data that lower pressure is not always better in blood-pressure control. Moreover, the author mentions that...

  • ASPIRIN ANOMALY. Gorman, Christine // Time;3/21/2005, Vol. 165 Issue 12, p85 

    Reports that a rigorously conducted clinical trial shows that a low dose of aspirin taken regularly, which seems to help middle-aged men avoid heart attacks, does not offer the same cardiovascular benefits for middle-aged women � although it does lessen their risk of stroke. Potential for a...

  • DECODE INITIATES PHASE IIA CLINICAL TRIAL FOR DG031.  // Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p1 

    Reports on the initiation of the phase IIa clinical trial of DG031, a developmental compound for the prevention of heart attack, deCODE genetics in 2004. Capabilities of the drug; Statement from deCODE CEO Kari Stefanson on the clinical trial; Schedule of the conclusion and presentation of the...

  • CLINIC ROUNDUP.  // BioWorld Today;11/23/2009, Vol. 20 Issue 226, p2 

    This section offers news briefs concerning clinical trials. Circassia Ltd. stated that nasal and ocular cat allergy symptoms were resolved by ToleroMune. A pilot melanoma study conducted by Genta Inc. found that Genasense produced a high objective response rate after being infused intravenously....

  • Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol. Moloudi, Abdolrasoul; Sabzi, Feridoun; Rashidi, Shirin // International Cardiovascular Research Journal;2012, Vol. 6 Issue 3, p88 

    Background: Retrospective studies and clinical trials have indicated that β-receptor blockers have an influential role in improving survival and reducing risk of recurrent infarction in patients with myocardial infarction. However, there is still controversy regarding the effects of...

  • The failure of antibiotics to prevent heart attacks. Taylor-Robinson, David; Boman, Jens // BMJ: British Medical Journal (International Edition);8/13/2005, Vol. 331 Issue 7513, p361 

    Presents an editorial regarding the failure of antibiotics in the prevention of heart attacks. Discussion of two clinical trials regarding the role of the respiratory pathogen Chlamydia pneumoniae in causing atherosclerotic cardiovascular disease; Description of a trial by Grayston and...

  • Far from the Heart: Receptor cross-talk in remote conditioning. Weber, Christian // Nature Medicine;Jul2010, Vol. 16 Issue 7, p760 

    The article discusses a clinical trial on remote ischemic conditioning that could help in reducing or preventing myocardial infarction. It cites the mechanisms that the researchers used in the study such as occlusion and reperfusion. It elaborates the role of cell as well as morphine and opioid...

  • 2008 - Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein. Campbell-Scherer, Denise L.; Montori, Victor M. // ACP Journal Club;1/1/2009, Vol. 150 Issue 1, p2 

    The article reports that in healthy older adults with elevated C-reactive protein levels who do not have hyperlipidemia, rosuvastatin reduced stroke and myocardial infarction. The randomized placebo-controlled trial titled "Justification for the Use of Statins in Prevention: An Intervention...

  • Aspirin and Risk of Hemorrhagic Stroke. He, Jiang; Whelton, Paul K.; Vu, Brian; Klag, Michael J. // JAMA: Journal of the American Medical Association;12/9/98, Vol. 280 Issue 22, p1930 

    Considers how aspirin has been widely used to prevent myocardial infarction in ischemic stroke, though some studies have suggested it increases the risk of hemorrhagic stroke. Study to estimate the risk of hemorrhagic stroke associated with aspirin treatment; Data sources; Study selection; Data...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics